Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

A Randomized Open-Label Study of the Impact of Quetiapine Versus Risperidone on Sexual Functioning

Knegtering, Rikus MD*; Castelein, Stynke MSc*; Bous, Han BA*; van der Linde, Just MD; Bruggeman, Richard MD, PhD*; Kluiter, Herman MSc, PhD*; van den Bosch, Robert J. MD, PhD*

Journal of Clinical Psychopharmacology: February 2004 - Volume 24 - Issue 1 - p 56-61
doi: 10.1097/
Original Contributions

Objective: To compare sexual functioning in patients treated with quetiapine or risperidone.

Methods: This open-label study included patients with schizophrenia or a related psychotic illness who were randomized to quetiapine (200-1200 mg/d) or risperidone (1-6 mg/d) for 6 weeks. Sexual dysfunction was assessed by a semistructured interview, the Antipsychotics and Sexual Functioning Questionnaire (ASFQ), based upon the Utvalg for Kliniske Undersogelser (UKU).

Results: Four of 25 quetiapine-treated patients (16%) and 12 of 24 risperidone-treated patients (50%) reported sexual dysfunction (χ 2 = 6.4; df = 1; P = 0.006) on the ASFQ. Six patients (11.7%; 4 on risperidone, 2 on quetiapine) spontaneously reported sexual dysfunction. The mean ± SD dose was 580 ± 224 mg/d for quetiapine and 3.2 ± 1.3 mg/d for risperidone. Mean ± SD prolactin levels in quetiapine- and risperidone-treated patients were 13.8 ± 17.9 and 57.7 ± 39.7 ng/mL, respectively.

Conclusion: Sexual dysfunction was less common in patients treated with quetiapine than with risperidone. Direct questioning about sexual functioning is necessary to avoid underestimating the frequency of sexual side effects in patients with schizophrenia and related psychotic disorders.

*Department of Psychiatry, University Hospital Groningen; †Center for Mental Healthcare Adhesie, Deventer, The Neteherlands.

Received January 29, 2003; accepted after revision July 10,2003.

Address correspondence and reprint requests to Rikus Knegtering, MD, Department of Psychiatry, University Hospital Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. E-mail: H.Knegtering@ACGGN.AZG.NL

© 2004 Lippincott Williams & Wilkins, Inc.